CD4 helper T cells, CD8 cytotoxic T cells, and FOXP3 + regulatory T cells with respect to lethal prostate cancer

Modern Pathology

Volumn 26, Issue 3, 2013, Pages 448-455

  Davidsson, Sabina ^a,b   Ohlson, Anna Lena ^a   Andersson, Swen Olof ^a,b   Fall, Katja ^a,b   Meisner, Allison ^c   Fiorentino, Michelangelo ^c,d   Andrén, Ove ^a,b   Rider, Jennifer R ^c,e  

^a ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^b ÖREBRO UNIVERSITY   (Sweden)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

CD4 helper T cells; CD8 cytotoxic T cells; FOXP3+ regulatory T cells; prostate cancer

Indexed keywords

TRANSCRIPTION FACTOR FOXP3;

AGED; ARTICLE; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER SURGERY; CANCER SURVIVAL; CASE CONTROL STUDY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; INCIDENTAL FINDING; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; REGULATORY T LYMPHOCYTE; TRANSURETHRAL RESECTION;

AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; INCIDENTAL FINDINGS; LOGISTIC MODELS; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; NEOPLASM STAGING; ODDS RATIO; PREDICTIVE VALUE OF TESTS; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; REGISTRIES; RISK ASSESSMENT; RISK FACTORS; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, HELPER-INDUCER; T-LYMPHOCYTES, REGULATORY; TIME FACTORS; TRANSURETHRAL RESECTION OF PROSTATE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; WATCHFUL WAITING;

EID: 84875209263     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2012.164     Document Type: Article

References (36)

1. Black RJ, Bray F, Ferlay J, et al. Cancer incidence and mortality in the European Union: cancer registry data and estimates of national incidence for 1990. Eur J Cancer 1997;33:1075-1107.
2. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
3. Burnet FM. The concept of immunological surveillance. Prog Exp Tumor Res 1970;13:1-27.
4. Nguyen T, Naziruddin B, Dintzis S, et al. Recognition of breast cancer-associated peptides by tumor-reactive, HLA-class I restricted allogeneic cytotoxic T lymphocytes. Int J Cancer 1999;81:607-615.
5. Appay V, Zaunders JJ, Papagno L, et al. Characterization of CD4(\+) CTLs ex vivo. J Immunol 2002;168: 5954-5958.
6. Carlos TM. Leukocyte recruitment at sites of tumor: dissonant orchestration. J Leukoc Biol 2001;70: 171-184.
7. Blumenfeld W, Tucci S, Narayan P. Incidental lymphocytic prostatitis. Selective involvement with nonmalignant glands. Am J Surg Pathol 1992;16:975-981.
8. Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. N Engl J Med 2003;349:366-381.
9. Aus G, Abbou CC, Bolla M, et al. EAU guidelines on prostate cancer. Eur Urol 2005;48:546-551.
10. De Marzo AM, Marchi VL, Epstein JI, et al. Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Pathol 1999; 155:1985-1992.
11. Vesalainen S, Lipponen P, Talja M, et al. Histological grade, perineural infiltration, tumour-infiltrating lymphocytes and apoptosis as determinants of longterm prognosis in prostatic adenocarcinoma. Eur J Cancer 1994;30A:1797-1803.
12. Irani J, Goujon JM, Ragni E, et al. High-grade inflammation in prostate cancer as a prognostic factor for biochemical recurrence after radical prostatectomy. Pathologist Multi Center Study Group. Urology 1999; 54:467-472.
13. Karja V, Aaltomaa S, Lipponen P, et al. Tumourinfiltrating lymphocytes: a prognostic factor of PSAfree survival in patients with local prostate carcinoma treated by radical prostatectomy. Anticancer Res 2005; 25:4435-4438.
14. McArdle PA, Canna K, McMillan DC, et al. The relationship between T-lymphocyte subset infiltration and survival in patients with prostate cancer. Br J Cancer 2004;91:541-543.
15. Fox SB, Launchbury R, Bates GJ, et al. The number of regulatory T cells in prostate cancer is associated with the androgen receptor and hypoxia-inducible factor (HIF)-2alpha but not HIF-1alpha. Prostate 2007;67: 623-629.
16. Kiniwa Y, Miyahara Y, Wang HY, et al. CD8\+ Foxp3\+ regulatory T cells mediate immunosuppression in prostate cancer. Clin Cancer Res 2007;13:6947-6958.
17. Miller AM, Lundberg K, Ozenci V, et al. CD4\+ CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol 2006;177:7398-7405.
18. Kono K, Kawaida H, Takahashi A, et al. CD4(\+) CD25high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers. Cancer Immunol Immunother 2006;55:1064-1071.
19. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003;299:1057-1061.
20. Andren O, Fall K, Franzen L, et al. How well does the Gleason score predict prostate cancer death? A 20-year followup of a population based cohort in Sweden J Urol 2006;17:1337-1340.
21. Aus G, Robinson D, Rosell J, et al. Survival in prostate carcinoma-outcomes from a prospective, populationbased cohort of 8887 men with up to 15 years of follow-up: results from three countries in the population-based National Prostate Cancer Registry of Sweden. Cancer 2005;103:943-951.
22. Johansson JE, Andren O, Andersson SO, et al. Natural history of early, localized prostate cancer. JAMA 2004;291:2713-2719.
23. Montironi R, Cheng L, Lopez-Beltran A, et al. Original Gleason system versus 2005 ISUP modified Gleason system: the importance of indicating which system is used in the patient's pathology and clinical reports. Eur Urol 2010;58:369-373.
24. Davidsson S, Fiorentino M, Andren O, et al. Inflammation, focal atrophic lesions, and prostatic intraepithelial neoplasia with respect to risk of lethal prostate cancer. Cancer Epidemiol Biomarkers Prev 2011;20:2280-2287.
25. Nishikawa H, Jager E, Ritter G, et al. CD4\+ CD25\+ regulatory T cells control the induction of antigenspecific CD4\+ helper T cell responses in cancer patients. Blood 2005;106:1008-1011.
26. Sfanos KS, Bruno TC, Maris CH, et al. Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing. Clin Cancer Res 2008;14: 3254-3261.
27. Yokokawa J, Cereda V, Remondo C, et al. Enhanced functionality of CD4\+CD25(high)FoxP3\+ regulatory Tcells in the peripheral blood of patients with prostate cancer. Clin Cancer Res 2008;14:1032-1040.
28. Sotosek S, Sotosek Tokmadzic V, Mrakovcic-Sutic I, et al. Comparative study of frequency of different lymphocytes subpopulation in peripheral blood of patients with prostate cancer and benign prostatic hyperplasia.Wien KlinWochenschr 2011;123:718-725.
29. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival Nat Med 2004;10:942-949.
30. Barrack ER. TGF beta in prostate cancer: a growth inhibitor that can enhance tumorigenicity. Prostate 1997;31:61-70.
31. Jakowlew SB. Transforming growth factor-beta in cancer and metastasis. Cancer Metastasis Rev 2006;25: 435-457.
32. Roncador G, Brown PJ, Maestre L, et al. Analysis of FOXP3 protein expression in human CD4\+CD25\+ regulatory T cells at the single-cell level. Eur J Immunol 2005;35:1681-1691.
33. Ebert LM, Tan BS, Browning J, et al. The regulatory T cell-associated transcription factor FoxP3 is expressed by tumor cells. Cancer Res 2008;68:3001-3009.
34. Valdman A, Jaraj SJ, Comperat E, et al. Distribution of Foxp3-, CD4-and CD8-positive lymphocytic cells in benign and malignant prostate tissue. APMIS 2010; 118:360-365.
35. Cohen RJ, Shannon BA, McNeal JE, et al. Propionibacterium acnes associated with inflammation in radical prostatectomy specimens: a possible link to cancer evolution? J Urol 2005;173:1969-1974.
36. Fassi Fehri L, Mak TN, Laube B, et al. Prevalence of Propionibacterium acnes in diseased prostates and its inflammatory and transforming activity on prostate epithelial cells. Int J Med Microbiol 2010;301:69-78.